arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Fulgent Genetics, Inc.

FLGT
$19.15 ▲ +0.59 (+3.18%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
46 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Fulgent Genetics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $536.3M
Dividend Yield
Revenue Growth 4.4%
Op. Margin -42.2%
ROIC -3.6%
FCF / Share $-0.99
Trailing P/E
Price / Book 0.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

46-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$85.39M
↑ +4.4%
Net Income Profit after all expenses
$-29.53M
↓ -55.8%
Operating Margin Operating profit as % of sales
-42.2%
↑ +13.2% 8th
FCF / Share Free cash flow per share
$-0.99
↓ -1707.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
38
Financial Health
3
Cash Quality
87

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 46 quarters